04/28/2016

Anapharm Europe’s First FDA Inspections

Anapharm Europe is proud to announce that it has successfully undergone its first US FDA inspection at its Barcelona based bioanalytical lab. Anapharm Europe is also registered in accordance with FDA’s “Generic Drug User Fee Amendments of 2012” requiring “Self-Identification of Generic Drug Facilities, Sites and Organizations”. This inspections will allow Anapharm to strengthen its position in North America and continue to help its customers achieve their registration goals in the United States.

Barcelona, April 27, 2016 Anapharm Europe is proud to announce that it has successfully undergone its first US FDA inspection at its Barcelona based bioanalytical lab. Anapharm Europe is also registered in accordance with FDA’s “Generic Drug User Fee Amendments of 2012” requiring “Self-Identification of Generic Drug Facilities, Sites and Organizations”. This inspections will allow Anapharm to strengthen its position in North America and continue to help its customers achieve their registration goals in the United States. About Anapharm Europe Over the past few years Anapharm Europe has established itself as a world class provider of bioanalytical services to international Sponsors with its strategically located, GLP-certified, ANVISA certified, GCP-compliant and FDA inspected laboratory in Barcelona. With a wide experience and a successful regulatory history, Anapharm Europe has become a stable analytical partner for its clients. Anapharm Europe’s main strengths include its strong expertise for method development and extensive portfolio of validated analytical methods, its high throughput capacity, as well as its top quality performance to deliver results within rigorous timelines at competitive prices.

MORE NEWS

03/06/2022 12:39

Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies

Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).

READ MORE
26/05/2022 11:39

Challenges in the determination of two analytes with different physicochemical properties, Tapinarof and its main metabolite, Tapinarof Sulfate, at the low picogram level

The challenge of developing a new bioanalytical method considerably increases when two or more metabolites need to be simultaneously analysed. Their extraction and chromatography optimization can be further complicated if their physicochemical properties vary significantly. Method development may be even more difficult when low limits of quantitation are required, for instance, when evaluating the systemic adsorption of topical drugs.

READ MORE
07/04/2022 10:15

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2024.

READ MORE